"The Cardiologs study shows that 24-hour Holter data can be used to enhance current monitoring capabilities, bringing hope to high-risk patients who would benefit from proactive treatment and AFib mitigation strategies,” says Singh. “By getting patients the care they need sooner and potentially preventing more severe outcomes, we could help save lives.”
The Cardiologs study demonstrates the capability of artificial intelligence in predicting AFib in the short-term using 24-hour Holter compared to resting 12-lead ECGs. While 12-lead ECG gives access to a larger view of the hearts' activity for a short period, 24-hour Holter provides longer-duration signals, therefore, offering additional inputs for predicting models.
The extension of AI capabilities towards predictions and digital biomarkers has the potential to bring improved health outcomes leading to new diagnostic paradigms. Predictive biomarkers may lead to early detection, enhanced patient monitoring, and improved patient management in general.
Philips’ portfolio of cardiac care solutions includes real-time patient monitoring, therapeutic devices, telehealth and informatics for the hospital, as well as ambulatory cardiac diagnostics and monitoring solutions. As part of Philips’ offering, Cardiologs is at the forefront of innovations that help set a new standard of patient care. Developed in partnership with leading physicians, Cardiologs’ technology accelerates diagnostic reporting, decreases the occurrence of reporting errors, and streamlines clinician workflow and patient care, empowering clinicians to deliver expert cardiac care faster and more efficiently.